CONy 2022 | Recent hot-button issues in headache research at CONy 2022
Dimos-Dimitrios Mitsikostas, MD, PhD, National & Kapodistrian University of Athens, Athens, Greece, gives an overview of the latest controversies in the field of headache treatment, including whether oral anti-calcitonin gene-related peptide (CGRP) medications or monoclonal antibodies are superior in the treatment of headaches. Additional contentious topics discussed include determining the optimal treatment strategy for symptomatic migraine attacks, as well as the pathogenesis of migraines. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.
Disclosures
Prof. Mitsikostas has received consulting, speaking fees and travel grants from Allergan, Amgen, Bayer, Biogen, Cefaly, Genesis Pharma, GlaxoSmithKline, ElectroCore, Eli Lilly, Merck-Serono, Merz, Mylan, Novartis, Roche, Sanofi- Genzyme, Specifar and Teva; Participated as principal investigator in randomised trials sponsored by Amgen, Eli-Lilly, ElectroCore, Merz, Novartis, Lundbeck, and Teva; Currently president of the Hellenic Headache Society, Co-Chairman of the Headache Scientific Panel at the European Academy of Neurology, and Co-Chairman of the Headache Section at CONy.
